{"id":"methotrexate-low-dose","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"10-20","effect":"Mucositis"},{"rate":"10-25","effect":"Nausea and vomiting"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"5-10","effect":"Alopecia"},{"rate":"5-15","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL2074969","moleculeType":"Small molecule","molecularWeight":"841.79"},"_fixedAt":"2026-03-30T17:34:55.129646","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate competitively inhibits dihydrofolate reductase, an enzyme essential for converting dihydrofolate to tetrahydrofolate, which is required for one-carbon transfer reactions in nucleotide synthesis. This disruption of DNA and RNA synthesis preferentially affects rapidly dividing cells, including cancer cells and activated immune cells. At low doses, methotrexate also has immunosuppressive and anti-inflammatory effects through adenosine release and other mechanisms.","oneSentence":"Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, blocking DNA synthesis and cell division in rapidly proliferating cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:58.351Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various malignancies (specific indication context-dependent on Case Comprehensive Cancer Center trial)"},{"name":"Autoimmune and inflammatory conditions (at low dose)"}]},"_fixedFields":["pubmed(2688)"],"trialDetails":[{"nctId":"NCT07497282","phase":"PHASE2","title":"Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-03-26","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT07428551","phase":"PHASE4","title":"Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients","status":"COMPLETED","sponsor":"Bangladesh Medical University","startDate":"2024-03-01","conditions":"Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Refractory Polyarticular Juvenile Idiopathic Arthritis","enrollment":50},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT07360340","phase":"","title":"Methotrexate Therapy and High-Resolution CT Chest and Spirometry Test Findings in Patients With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-12-01","conditions":"Methohexitone Pulmonary Adverse Reaction","enrollment":50},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT07161336","phase":"PHASE2","title":"Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-07-30","conditions":"Osteo Arthritis of the Knee, Synovitis of Knee, Methotrexate","enrollment":70},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT06882057","phase":"PHASE2, PHASE3","title":"Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":3000},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT04562558","phase":"NA","title":"Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"xiang yang","startDate":"2020-09-29","conditions":"Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia, Stage I Gestational Trophoblastic Tumor","enrollment":228},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT05132166","phase":"PHASE2","title":"A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-22","conditions":"Graft Vs Host Disease","enrollment":50},{"nctId":"NCT04838704","phase":"NA","title":"Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-04-01","conditions":"Graft Versus Host Disease","enrollment":215},{"nctId":"NCT07002099","phase":"PHASE2","title":"Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Lymphomas","enrollment":26},{"nctId":"NCT01554696","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-07-06","conditions":"Arthritis, Rheumatoid","enrollment":379},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT06965244","phase":"PHASE3","title":"Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-10-01","conditions":"Cutaneous Lupus Erythematosus (CLE)","enrollment":122},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT03505008","phase":"PHASE4","title":"Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan","status":"COMPLETED","sponsor":"Keio University","startDate":"2018-04-18","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT02852694","phase":"PHASE4","title":"Reduce Risk for Crohn's Disease Patients","status":"COMPLETED","sponsor":"PIBD-Net","startDate":"2017-02-28","conditions":"Crohn's Disease","enrollment":192},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03635957","phase":"PHASE4","title":"Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-09-26","conditions":"Gout","enrollment":14},{"nctId":"NCT03994731","phase":"PHASE4","title":"Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-13","conditions":"Gout","enrollment":152},{"nctId":"NCT05926492","phase":"PHASE2","title":"A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-09","conditions":"Osteosarcoma","enrollment":160},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT06300333","phase":"","title":"Treatment of Ectopic Pregnancy by Low Dose of Methotrexate","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-03","conditions":"Ectopic Pregnancy","enrollment":20},{"nctId":"NCT06217224","phase":"NA","title":"Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2022-10-17","conditions":"Mucositis Oral","enrollment":53},{"nctId":"NCT03371667","phase":"PHASE3","title":"To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-08-16","conditions":"Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute","enrollment":102},{"nctId":"NCT06175702","phase":"","title":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-12-25","conditions":"Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL","enrollment":150},{"nctId":"NCT06154590","phase":"","title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","status":"NOT_YET_RECRUITING","sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","startDate":"2024-07","conditions":"Metastatic Breast Cancer, Tumor, Muscle Neoplasms","enrollment":100},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT00577122","phase":"PHASE2","title":"Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Indiana University","startDate":"2007-07","conditions":"Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer","enrollment":30},{"nctId":"NCT01951885","phase":"PHASE3","title":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-07-07","conditions":"Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT00101101","phase":"PHASE2","title":"Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2004-07","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT01399372","phase":"PHASE2","title":"Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-09","conditions":"Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma","enrollment":91},{"nctId":"NCT02772965","phase":"PHASE3","title":"Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-10","conditions":"Pediatric Crohn's Disease","enrollment":306},{"nctId":"NCT00005585","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-04","conditions":"Leukemia","enrollment":838},{"nctId":"NCT01285817","phase":"PHASE2","title":"A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2011-01-12","conditions":"Survival Without Progression","enrollment":79},{"nctId":"NCT05634915","phase":"PHASE4","title":"Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-20","conditions":"Hematopoietic Stem Cell Transplantation, Acute Leukemia","enrollment":90},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT00912223","phase":"PHASE2","title":"Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2009-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":65},{"nctId":"NCT03286634","phase":"PHASE2","title":"ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016","status":"RECRUITING","sponsor":"National Hospital Organization Nagoya Medical Center","startDate":"2017-04-18","conditions":"Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer","enrollment":60},{"nctId":"NCT03088293","phase":"PHASE3","title":"Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2020-06-11","conditions":"Idiopathic Refractory Scleritis","enrollment":""},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT00000658","phase":"PHASE3","title":"A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Lymphoma, Non-Hodgkin, HIV Infections","enrollment":250},{"nctId":"NCT01949116","phase":"PHASE2","title":"Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-31","conditions":"HIV Infections","enrollment":176},{"nctId":"NCT02124226","phase":"PHASE3","title":"Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma","status":"UNKNOWN","sponsor":"Universita degli Studi di Catania","startDate":"2021-12","conditions":"Low Dose Methotrexate in Severe Chronic Asthma","enrollment":102},{"nctId":"NCT02067143","phase":"PHASE2","title":"MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2014-05-20","conditions":"Untreated Philadelphia Positive Acute Lymphoblastic Leukemia, De Novo, Secondary","enrollment":204},{"nctId":"NCT01663766","phase":"PHASE1","title":"Phase I Study of Milatuzumab for Graft Versus Host Disease","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-12","conditions":"GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome","enrollment":12},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT00860574","phase":"PHASE2","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":96},{"nctId":"NCT00103285","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-04-11","conditions":"Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":5377},{"nctId":"NCT03275025","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2017-04-01","conditions":"Rheumatoid Arthritis","enrollment":116},{"nctId":"NCT01851707","phase":"PHASE2","title":"A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":322},{"nctId":"NCT00296010","phase":"PHASE3","title":"Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2005-08","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT02786134","phase":"NA","title":"Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-04","conditions":"Coronary Heart Disease, Metabolic Syndrome, Diabetes Mellitus","enrollment":50},{"nctId":"NCT03605251","phase":"PHASE2","title":"Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2018-08-30","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT01594333","phase":"PHASE3","title":"Cardiovascular Inflammation Reduction Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2013-04","conditions":"Cardiovascular Disease","enrollment":4786},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT02576067","phase":"PHASE3","title":"Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-12-18","conditions":"Vascular Inflammation, Atherosclerotic Cardiovascular Disease","enrollment":123},{"nctId":"NCT02280694","phase":"PHASE2","title":"Low Dose Metronomic Poly-chemotherapy for Metastatic CRC","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2015-01","conditions":"Colorectal Cancer","enrollment":45},{"nctId":"NCT01953770","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2008-02","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":3000},{"nctId":"NCT01823315","phase":"PHASE3","title":"Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia","status":"UNKNOWN","sponsor":"Ding Ma","startDate":"2012-12","conditions":"Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia, Gestational Trophoblastic Tumor","enrollment":300},{"nctId":"NCT00392990","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-02-06","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT02644499","phase":"PHASE4","title":"Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":186},{"nctId":"NCT01529827","phase":"PHASE2","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-02-28","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":94},{"nctId":"NCT02265705","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT02467504","phase":"PHASE2","title":"Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2015-07-01","conditions":"Rheumatoid Arthritis","enrollment":47},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT01432145","phase":"PHASE2","title":"A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-05","conditions":"Breast Cancer, Ovarian Cancer","enrollment":74},{"nctId":"NCT00083031","phase":"PHASE2","title":"Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2003-07","conditions":"Breast Cancer","enrollment":57},{"nctId":"NCT02312219","phase":"","title":"PET/CT Imaging Companion Study To ACTG A5314","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-11","conditions":"HIV, Inflammation, Atherosclerosis","enrollment":35},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT03813771","phase":"PHASE4","title":"Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2019-03","conditions":"Rheumatoid Arthritis","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2688,"recentPublications":[{"date":"2026 Mar 16","pmid":"41863230","title":"Nutritional Implications of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis.","journal":"Reviews on recent clinical trials"},{"date":"2006","pmid":"30000400","title":"Methotrexate.","journal":""},{"date":"2026 Mar 6","pmid":"41827429","title":"Low-Dose Methotrexate and Bone Health: Pathophysiological and Clinical Perspectives.","journal":"Journal of clinical medicine"},{"date":"2026 Mar 11","pmid":"41814058","title":"Development of EL/PLGA nanoparticles for oral delivery of methotrexate with enhanced bioavailability and reduced toxicity.","journal":"Drug delivery and translational research"},{"date":"2026 Apr","pmid":"41810147","title":"Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial.","journal":"The Lancet regional health. Southeast Asia"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["amethopterin","Folex","methylaminopterin","Mexate","MTX"],"phase":"phase_3","status":"active","brandName":"Methotrexate (low dose)","genericName":"Methotrexate (low dose)","companyName":"Case Comprehensive Cancer Center","companyId":"case-comprehensive-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, blocking DNA synthesis and cell division in rapidly proliferating cells. Used for Various malignancies (specific indication context-dependent on Case Comprehensive Cancer Center trial), Autoimmune and inflammatory conditions (at low dose).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}